IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 101–200 of 1,012

1. Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
   Barbara S. Paugh, Chunxu Qu, Chris Jones, Zhaoli Liu, Martyna Adamowicz‐Brice, Junyuan Zhang, Dorine A. Bax, Beth Coyle, Jennifer Barrow, Darren R. Hargrave et al. · 2010 · Journal of Clinical Oncology
2. Metabolomics in cancer research and emerging applications in clinical oncology
   Daniel R. Schmidt, Rutulkumar Patel, David G. Kirsch, Caroline A. Lewis, Matthew G. Vander Heiden, Jason W. Locasale · 2021 · CA A Cancer Journal for Clinicians
3. Transcription factors as readers and effectors of DNA methylation
   Zhu, Heng, Wang, Guohua, Qian, Jiang · 2016 · Nature Reviews Genetics
4. Targeting the epigenetic regulation of antitumour immunity
   Simon J. Hogg, Paul A. Beavis, Mark A. Dawson, Ricky W. Johnstone · 2020 · Nature Reviews Drug Discovery
5. Cancer genomics: from discovery science to personalized medicine
   Lynda Chin, Jannik N. Andersen, P. Andrew Futreal · 2011 · Nature Medicine
6. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
   Kurt Alex Schalper, Maria Esperanza Rodriguez-Ruiz, Ricardo Díez-Valle, Álvaro López‐Janeiro, Angelo Porciuncula, Miguel Angel Idoate, Susana Inogés, Carlos de Andrea, Ascensión López-Dı́az de Cerio, Sonia Tejada et al. · 2019 · Nature Medicine
7. IDH1 and IDH2 mutations in gliomas
   Cohen, Adam L., Holmen, Sheri L., Colman, Howard · 2013 · Current Neurology and Neuroscience Reports
8. Glioma
   Michael Weller, Patrick Yung Wen, Susan Marina Chang, Linda Dirven, Michael K. Lim, Michelle Monje, Guido Reifenberger · 2024 · Nature Reviews Disease Primers
9. Acute myeloid leukaemia
   Asim Khwaja, Magnus Björkholm, Rosemary E. Gale, Ross L. Levine, Craig T. Jordan, Gerhard Ehninger, Clara Derber Bloomfield, Elihu H. Estey, Alan K. Burnett, Jan J. Cornelissen et al. · 2016 · Nature Reviews Disease Primers
10. Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
    Michael Weller, Jörg Felsberg, Christian Johannes Hartmann, Hilmar Berger, Joachim Peter Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg Christian Tonn et al. · 2009 · Journal of Clinical Oncology
11. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer
    Nilsson, Roland, Jain, Mohit, Madhusudhan, Nikhil, Sheppard, Nina Gustafsson, Strittmatter, Laura, Kampf, Caroline, Huang, Jenny, Asplund, Anna, Mootha, Vamsi K. · 2014 · Nature Communications
12. CGCG clinical practice guidelines for the management of adult diffuse gliomas
    Tao Jiang, Ying Qing Mao, Wenbin Ma, Qing Mao, Yongping You, Xuejun Yang, Chuanlu Jiang, Chunsheng Kang, Xuejun Li, Ling Chen et al. · 2016 · Cancer Letters
13. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host
    Winston Timp, A. Feinberg · 2013 · Nature Reviews. Cancer
14. The Mitochondrial Proteome and Human Disease
    Calvo, Sarah E., Mootha, Vamsi K. · 2010 · Annual Review of Genomics and Human Genetics
15. Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
    Yuchen Jiao, Patrick J. Killela, Zachary J. Reitman, B. Ahmed Rasheed, Christopher M. Heaphy, Roeland F. de Wilde, Fausto J. Rodríguez, Sérgio Rosemberg, Sueli Mieko Oba‐Shinjo, Suely Kazue Nagahashi Marie et al. · 2012 · Oncotarget
16. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
    Steven M. Chan, Danièl Thomas, M. Ryan Corces, Seethu Xavy, Suchita Rastogi, Wan‐Jen Hong, Feifei Zhao, Bruno C. Medeiros, David A. Tyvoll, Ravindra Majeti · 2015 · Nature Medicine
17. Microfluidic isolation and transcriptome analysis of serum microvesicles
    Chen, Chihchen, Skog, Johan, Hsu, Chia-Hsien, Lessard, Ryan T., Balaj, Leonora, Wurdinger, Thomas, Carter, Bob S., Breakefield, Xandra O., Toner, Mehmet, Irimia, Daniel · 2010 · Lab Chip
18. What a difference a hydroxyl makes: mutant IDH, (<i>R</i>)-2-hydroxyglutarate, and cancer
    Losman, Julie-Aurore, Kaelin, William G. · 2013 · Genes &amp; Development
19. Emerging insights into the molecular and cellular basis of glioblastoma
    Gavin P. Dunn, Mikael L. Rinne, Jill Wykosky, Giannicola Genovese, Steven N. Quayle, Ian F. Dunn, Pankaj Kumar Agarwalla, Milan G. Chheda, Benito Campos, Alan Wang et al. · 2012 · Genes & Development
20. Longitudinal molecular trajectories of diffuse glioma in adults
    Floris P Barthel, Kevin C. Johnson, Frederick S. Varn, Anzhela D. Moskalik, Georgette Tanner, Emre Kocakavuk, Kevin J. Anderson, Olajide Abiola, Kenneth Aldape, Kristin D. Alfaro-Munoz et al. · 2019 · Nature
21. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism
    Reitman, Z. J., Yan, H. · 2010 · JNCI Journal of the National Cancer Institute
22. Regulation of the pentose phosphate pathway in cancer
    Peng Jiang, Wenjing Du, Mian Wu · 2014 · Protein & Cell
23. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
    Pansuriya, Twinkal C, van Eijk, Ronald, d'Adamo, Pio, van Ruler, Maayke A J H, Kuijjer, Marieke L, Oosting, Jan, Cleton-Jansen, Anne-Marie, van Oosterwijk, Jolieke G, Verbeke, Sofie L J, Meijer, Daniëlle et al. · 2011 · Nature Genetics
24. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
    Parker L. Sulkowski, Christopher D. Corso, Nathaniel D. Robinson, Susan E. Scanlon, Karin R. Purshouse, Hanwen Bai, Yanfeng Liu, Ranjini K. Sundaram, Denise Campisi Hegan, Nathan R. Fons et al. · 2017 · Science Translational Medicine
25. Anticancer Activity of Metal Complexes: Involvement of Redox Processes
    Ute Jungwirth, Christian R. Kowol, Bernhard K. Keppler, Christian G. Hartinger, Walter Berger, Petra Heffeter · 2011 · Antioxidants and Redox Signaling
26. The emerging role and targetability of the TCA cycle in cancer metabolism
    Nicole M. Anderson, Patrick Mucka, Joseph G. Kern, Hui Feng · 2017 · Protein & Cell
27. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
    Sturm, Dominik, Bender, Sebastian, Jones, David T. W., Lichter, Peter, Grill, Jacques, Becher, Oren, Hawkins, Cynthia, Majewski, Jacek, Jones, Chris, Costello, Joseph F. et al. · 2014 · Nature Reviews Cancer
28. Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
    Chetan Bettegowda, Nishant Agrawal, Yuchen Jiao, Mark Sausen, Laura DeLong Wood, Ralph H. Hruban, Fausto J. Rodríguez, Daniel P. Cahill, Roger E. McLendon, Gregory Joseph Riggins et al. · 2011 · Science
29. Glioblastoma multiforme: a review of where we have been and where we are going
    Cory Adamson, Okezie Obasi Kanu, Ankit Indravadan Mehta, Chunhui Di, Ningjing Lin, Austin K. Mattox, Darell D. Bigner · 2009 · Expert Opinion on Investigational Drugs
30. Glioma epigenetics: From subclassification to novel treatment options
    Olga Gusyatiner, Monika E. Hegi · 2017 · Seminars in Cancer Biology
31. Mitochondria as playmakers of apoptosis, autophagy and senescence
    Marianna Abate, Agostino Festa, Michela Falco, Angela Lombardi, Amalia Luce, Anna Grimaldi, Silvia Zappavigna, Pasquale Sperlongano, Carlo Irace, Michele Caraglia et al. · 2019 · Seminars in Cell and Developmental Biology
32. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis
    Agathocleous, Michalis, Meacham, Corbin E., Burgess, Rebecca J., Piskounova, Elena, Zhao, Zhiyu, Crane, Genevieve M., Cowin, Brianna L., Bruner, Emily, Murphy, Malea M., Chen, Weina et al. · 2017 · Nature
33. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
    Burt Nabors, Jana Portnow, Manmeet Singh Ahluwalia, Joachim M. Baehring, Henry Brem, Steven S. Brem, Nicholas Arthur Butowski, Jian Li Campian, Stephen W. Clark, Andrew J. Fabiano et al. · 2020 · Journal of the National Comprehensive Cancer Network
34. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
    Caroline Houillier, X. Wang, Gentian Kaloshi, Karima Mokhtari, Rémy Guillevin, Julien Laffaire, Sophie Paris, Blandine Boisselier, Ahmed Idbaïh, Florence Laigle–Donadey et al. · 2010 · Neurology
35. Fatty acid oxidation: An emerging facet of metabolic transformation in cancer
    Yibao Ma, Sarah Madhu Temkin, Adam M. Hawkridge, Chunqing Guo, Wei Wang, Xiang‐Yang Wang, Xianjun Fang · 2018 · Cancer Letters
36. Regulation and function of the mammalian tricarboxylic acid cycle
    Arnold, Paige K., Finley, Lydia W.S. · 2023 · Journal of Biological Chemistry
37. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
    Ayalew Tefferi · 2010 · Leukemia
38. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations
    Cameron Walter Brennan, Hiroyuki Momota, Dolores Hambardzumyan, Tatsuya Ozawa, Adesh Tandon, Alicia M. Pedraza, Eric C. Holland · 2009 · PLoS ONE
39. Superoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential
    Ines Batinic̈‐Haberle, Julio Santos Reboucas, Ivan Spasojević · 2010 · Antioxidants and Redox Signaling
40. TERT PROMOTER MUTATIONS OCCUR FREQUENTLY IN GLIOMAS AND A SUBSET OF TUMORS DERIVED FROM CELLS WITH LOW RATES OF SELF-RENEWAL
    Hai Yan, Patrick J. Killela, Zachary J. Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, L. A. Diaz, Allan H. Friedman, Henry S. Friedman, Gary L. Gallia et al. · 2014 · Neuro-Oncology
41. Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
    Jian Chen, Renée M. McKay, Luis F. Parada · 2012 · Cell
42. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
    David Capper, Susanne Weißert, Jörg Balß, Antje Habel, Jochen Meyer, D. Jaeger, Ulrike Ackermann, Claudia Tessmer, Andrey Korshunov, Hanswalter Zentgraf et al. · 2009 · Brain Pathology
43. Epidemiology and Outcome of Glioblastoma
    Ahmad Tamimi, Malik Eid Juweid · 2017 · Codon Publications eBooks
44. Glioblastoma: From Molecular Pathology to Targeted Treatment
    Timothy Francis Cloughesy, Webster K. Cavenee, Paul S. Mischel · 2011 · Annual Review of Pathology Mechanisms of Disease
45. The impact of cellular metabolism on chromatin dynamics and epigenetics
    Reid, Michael A., Dai, Ziwei, Locasale, Jason W. · 2017 · Nature Cell Biology
46. Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
    Meghan J. Seltzer, Bryson D. Bennett, Avadhut D. Joshi, Ping Gao, Ajit G. Thomas, Dana V. Ferraris, Takashi Tsukamoto, Camilo J. Rojas, Barbara Stauch Slusher, Joshua D. Rabinowitz et al. · 2010 · Cancer Research
47. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake
    William A. Flavahan, Qiulian Wu, Masahiro Hitomi, Nasiha Rahim, Youngmi Kim, Andrew Edward Sloan, Robert John Weil, Ichiro Nakano, Jann Nagina Sarkaria, Brett William Stringer et al. · 2013 · Nature Neuroscience
48. IDH mutations in cancer and progress toward development of targeted therapeutics
    Dang, L., Yen, K., Attar, E.C. · 2016 · Annals of Oncology
49. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
    Rob A. Cairns, Javeed Iqbal, François Lemonnier, Can Küçük, Laurence de Leval, Jean‐Philippe Jaïs, Marie Parrens, Antoine Martin, Luc Xerri, Pierre Brousset et al. · 2012 · Blood
50. Mitochondrial Dysfunction in Cancer
    Michelle L. Boland, Aparajita H. Chourasia, Kay F. Macleod · 2013 · Frontiers in Oncology
51. Glioma progression is shaped by genetic evolution and microenvironment interactions
    Frederick S. Varn, Kevin C. Johnson, Jan Martinek, Jason T. Huse, MacLean P. Nasrallah, Pieter Wesseling, Lee Cooper, Tathiane Maistro Malta, Taylor E. Wade, Thaís S. Sabedot et al. · 2022 · Cell
52. New aspects of amino acid metabolism in cancer
    Lisa A. Vettore, Rebecca L. Westbrook, Daniel A. Tennant · 2019 · British Journal of Cancer
53. The evolving metabolic landscape of chromatin biology and epigenetics
    Ziwei Dai, Vijyendra Ramesh, Jason W. Locasale · 2020 · Nature Reviews Genetics
54. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
    Baumert, Brigitta G, Hegi, Monika E, van den Bent, Martin J, von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A, Kantor, Guy, Taphoorn, Martin J B, Hassel, Mohamed Ben et al. · 2016 · The Lancet Oncology
55. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1
    Tönjes, Martje, Barbus, Sebastian, Park, Yoon Jung, Wang, Wei, Schlotter, Magdalena, Lindroth, Anders M, Pleier, Sabrina V, Bai, Alfa H C, Karra, Daniela, Piro, Rosario M et al. · 2013 · Nature Medicine
56. Glioblastoma
    Hans‐Georg Wirsching, Evanthia Galanis, Michael Weller · 2016 · Handbook of clinical neurology
57. 3D cell culture systems modeling tumor growth determinants in cancer target discovery
    Thoma, Claudio R., Zimmermann, Miriam, Agarkova, Irina, Kelm, Jens M., Krek, Wilhelm · 2014 · Advanced Drug Delivery Reviews
58. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas
    Scott T. Ryall, Michal Zápotocký, Kohei Fukuoka, Liana Figueiredo Nobre, Ana Guerreiro Stücklin, Julie Bennett, Robert Siddaway, Christopher Li, Sanja Pajovic, Anthony Arnoldo et al. · 2020 · Cancer Cell
59. Maximizing safe resection of low- and high-grade glioma
    Shawn L. Hervey‐Jumper, Mitchel Stuart Berger · 2016 · Journal of Neuro-Oncology
60. Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas
    Peter D. Chang, Jack Grinband, Brent D. Weinberg, Michelle D. Bardis, M. Khy, G. Cadena, Min‐Ying Su, Soonmee Cha, Christopher G. Filippi, Daniela Annenelie Bota et al. · 2018 · American Journal of Neuroradiology
61. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
    Yen, Katharine, Travins, Jeremy, Wang, Fang, David, Muriel D., Artin, Erin, Straley, Kimberly, Padyana, Anil, Gross, Stefan, DeLaBarre, Byron, Tobin, Erica et al. · 2017 · Cancer Discovery
62. A Review on a Deep Learning Perspective in Brain Cancer Classification
    Gopal Singh Tandel, Mainak Biswas, Omprakash G. Kakde, Ashish Tiwari, Harman S. Suri, Monica Turk, John R. Laird, Christopher K Asare, Annabel A. Ankrah, Narendra Nath Khanna et al. · 2019 · Cancers
63. Diffuse Glioma Heterogeneity and Its Therapeutic Implications
    James Nicholson, Howard Alan Fine · 2021 · Cancer Discovery
64. The mutational landscape of adenoid cystic carcinoma
    Allen S. Ho, Kasthuri S. Kannan, David M. Roy, Luc G.T. Morris, Ian Ganly, Nora Katabi, Deepa Ramaswami, Logan A. Walsh, Stephanie Eng, Jason T. Huse et al. · 2013 · Nature Genetics
65. IDH1andIDH2Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
    Hui Yang, Dan Ye, Kun‐Liang Guan, Yue Xiong · 2012 · Clinical Cancer Research
66. Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations
    Hannah K. Carter, Sining Chen, Leyla Işık, Svitlana Tyekucheva, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Rachel Karchin · 2009 · Cancer Research
67. Recent advances in the molecular understanding of glioblastoma
    Fonnet E. Bleeker, Remco Jurriaan Molenaar, Sieger Leenstra · 2012 · Journal of Neuro-Oncology
68. Imbalanced GSH/ROS and sequential cell death
    Ting Liu, Li Sun, Yubin Zhang, Yonglin Wang, Jiang Zheng · 2021 · Journal of Biochemical and Molecular Toxicology
69. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
    Mitsuaki Shirahata, Takahiro Ono, Damian Stichel, Daniel Schrimpf, David Reuß, Felix Sahm, Christian Koelsche, Annika K. Wefers, Annekathrin Reinhardt, Kristin T. L. Huang et al. · 2018 · Acta Neuropathologica
70. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection
    Beiko, Jason, Suki, Dima, Hess, Kenneth R., Fox, Benjamin D., Cheung, Vincent, Cabral, Matthew, Shonka, Nicole, Gilbert, Mark R., Sawaya, Raymond, Prabhu, Sujit S. et al. · 2014 · Neuro-Oncology
71. Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
    Cairns, Rob A., Mak, Tak W. · 2013 · Cancer Discovery
72. Genetic alterations and signaling pathways in the evolution of gliomas
    Hiroko Ohgaki, Paul Kleihues · 2009 · Cancer Science
73. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
    Reitman, Zachary J., Jin, Genglin, Karoly, Edward D., Spasojevic, Ivan, Yang, Jian, Kinzler, Kenneth W., He, Yiping, Bigner, Darell D., Vogelstein, Bert, Yan, Hai · 2011 · Proceedings of the National Academy of Sciences
74. 5-Hydroxymethylcytosine Is Strongly Depleted in Human Cancers but Its Levels Do Not Correlate with IDH1 Mutations
    Seung‐Gi Jin, Yong Jiang, Runxiang Qiu, Tibor A. Rauch, Yinsheng Wang, Gabriele Schackert, Dietmar Krex, Qiang Lü, Gerd P. Pfeifer · 2011 · Cancer Research
75. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
    David Reuß, Felix Sahm, Daniel Schrimpf, Benedikt Wiestler, David Capper, Christian Koelsche, Leonille Schweizer, Andrey Korshunov, David Jones, Volker Hovestadt et al. · 2014 · Acta Neuropathologica
76. Survival and low-grade glioma: the emergence of genetic information
    Elizabeth B. Claus, Kyle M. Walsh, John K. Wiencke, Annette M. Molinaro, Joseph Leo Wiemels, Joellen M. Schildkraut, Melissa L. Bondy, Mitchel Stuart Berger, Robert Brian Jenkins, Margaret Wrensch · 2015 · Neurosurgical FOCUS
77. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α
    Sascha Seidel, Boyan K. Garvalov, Valtteri Wirta, Louise von Stechow, Anne Schänzer, Konstantinos Meletis, Marietta Wolter, Daniel Sommerlad, Anne‐Theres Henze, Monica Nistér et al. · 2010 · Brain
78. Glioblastoma targeted therapy: updated approaches from recent biological insights
    Mehdi Touat, Ahmed Idbaïh, Marc Sanson, Keith Lloyd Ligon · 2017 · Annals of Oncology
79. Detection of 2-Hydroxyglutarate in <i>IDH</i> -Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
    Andronesi, Ovidiu C., Kim, Grace S., Gerstner, Elizabeth, Batchelor, Tracy, Tzika, Aria A., Fantin, Valeria R., Vander Heiden, Matthew G., Sorensen, A. Gregory · 2012 · Science Translational Medicine
80. Monoclonal antibody specific for IDH1 R132H mutation
    David Capper, Hanswalter Zentgraf, Jörg Balß, Christian Johannes Hartmann, Andreas von Deimling · 2009 · Acta Neuropathologica
81. Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology Group
    Joann L. Ater, Tianni Zhou, Emiko J. Holmes, Claire Mazewski, Timothy N. Booth, David R. Freyer, Ken H. Lazarus, Roger J. Packer, Michael D. Prados, Richard Sposto et al. · 2012 · Journal of Clinical Oncology
82. Clinical practice guidelines for the management of adult diffuse gliomas
    Tao Jiang, Do‐Hyun Nam, Zvi Ram, Wai Sang Poon, Jiguang Wang, Damdindorj Boldbaatar, Ying Qing Mao, Wenbin Ma, Qing Mao, Yongping You et al. · 2020 · Cancer Letters
83. Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
    Albert Lai, Samir Kharbanda, Whitney B. Pope, Anh Nhat Tran, Orestes E. Solis, Franklin V. Peale Jr., William F. Forrest, Kanan Pujara, Jose Carrillo, Ajay Pandita et al. · 2011 · Journal of Clinical Oncology
84. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
    Tateishi, Kensuke, Wakimoto, Hiroaki, Iafrate, A. John, Tanaka, Shota, Loebel, Franziska, Lelic, Nina, Wiederschain, Dmitri, Bedel, Olivier, Deng, Gejing, Zhang, Bailin et al. · 2015 · Cancer Cell
85. A vaccine targeting mutant IDH1 in newly diagnosed glioma
    Michael Platten, Lukas Bunse, Antje Wick, Theresa Bunse, Lucian Le Cornet, Inga Harting, Felix Sahm, Khwab Sanghvi, Chin Leng Tan, Isabel C. Poschke et al. · 2021 · Nature
86. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
    Xiao-Yang Liu, Noha Gerges, Andrey Korshunov, Nesrin Sabha, Dong-Anh Khuong-Quang, Adam M. Fontebasso, Adam J. Fleming, Djihad Hadjadj, Jeremy Schwartzentruber, Jacek Majewski et al. · 2012 · Acta Neuropathologica
87. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
    Helai P. Mohammad, Olena Barbash, Caretha L. Creasy · 2019 · Nature Medicine
88. Oncometabolites: linking altered metabolism with cancer
    Ming Hui Yang, Tomoyoshi Soga, Patrick J. Pollard · 2013 · Journal of Clinical Investigation
89. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
    James M. Schuster, R. K. Lai, Lawrence David Recht, David A. Reardon, Nina A. Paleologos, Morris D. Groves, Maciej M. Mrugała, Randy L. Jensen, Joachim M. Baehring, Andrew Edward Sloan et al. · 2015 · Neuro-Oncology
90. T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project
    Sohil Harshad Patel, Laila Poisson, Daniel Jay Brat, Yueren Zhou, Lee Cooper, Matija Snuderl, Cheddhi Thomas, Ana Marija Franceschi, Brent D Griffith, Adam Eugene Flanders et al. · 2017 · Clinical Cancer Research
91. Metabolic control of epigenetics in cancer
    Adam S. Kinnaird, Steven Zhao, Kathryn E. Wellen, Evangelos D. Michelakis · 2016 · Nature reviews. Cancer
92. Molecular markers in glioma
    Kirsten Ludwig, Harley I. Kornblum · 2017 · Journal of Neuro-Oncology
93. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors
    Sosipatros Alexandros Boikos, Alberto S. Pappo, J. Keith Killian, Michael P. LaQuaglia, Christopher Bertero Weldon, Suzanne George, Jonathan C. Trent, Margaret von Mehren, Jennifer A. Wright, J. D. Schiffman et al. · 2016 · JAMA Oncology
94. Mitochondrial control by DRP1 in brain tumor initiating cells
    Qi Xie, Qiulian Wu, Craig Horbinski, William A. Flavahan, Kailin Yang, Wenchao Zhou, Stephen M. Dombrowski, Zhi Huang, Xiaoguang Fang, Yu Shi et al. · 2015 · Nature Neuroscience
95. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
    Gary Kohanbash, Diego A. Carrera, Shruti Shrivastav, Brian J. Ahn, Naznin Jahan, Tali Mazor, Zinal S. Chheda, Kira Downey, Payal B. Watchmaker, Casey Beppler et al. · 2017 · Journal of Clinical Investigation
96. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas
    Zhaoshi Bao, Hui-Min Chen, Ming-Yu Yang, Chuan‐Bao Zhang, Kai Yu, Wan-Lu Ye, Bo-Qiang Hu, Wei Yan, Wei Zhang, Johnny C. Akers et al. · 2014 · Genome Research
97. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology
    Ibrahim A. Qaddoumi, Wilda Orisme, Ji Wen, Teresa Santiago, Kirti Gupta, James Dalton, Bo Tang, Kelly Haupfear, Chandanamali Punchihewa, John B. Easton et al. · 2016 · Acta Neuropathologica
98. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
    Michael O. Krauthammer, Yong Kong, Antonella Bacchiocchi, Perry Evans, Natapol Pornputtapong, Cen Wu, Jamie Patricia McCusker, Shuangge Ma, Elaine Cheng, Robert Straub et al. · 2015 · Nature Genetics
99. Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
    John Gregory Cairncross, Meihua Wang, Robert Brian Jenkins, Edward G. Shaw, Caterina Giannini, David G Brachman, Jan C. Buckner, Karen Fink, Luís Souhami, Normand Laperrière et al. · 2014 · Journal of Clinical Oncology
100. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
     Wang, P, Dong, Q, Zhang, C, Kuan, P-F, Liu, Y, Jeck, W R, Andersen, J B, Jiang, W, Savich, G L, Tan, T-X et al. · 2013 · Oncogene